September 14, 2016
Wellesley, Mass., Sep 14, 2016 – An aging global population and the increasing worldwide prevalence of cardiovascular disease have created new opportunities for antithrombotic/anticoagulant drug products. BCC Research reveals in its new report that a variety of novel antithrombotic/anticoagulants offer better pharmacological and clinical profiles than those associated with traditional therapies.
Antithrombotic drugs comprise two classes of drugs: anticoagulants and antiplatelet drugs. Anticoagulants slow clotting, thereby reducing fibrin formation and preventing clots from forming and growing. They are widely used as blood thinners in patients suffering from heart attacks and other heart-related diseases. Antiplatelet agents prevent platelets from clumping and also prevent clots from forming and growing. The global market is segmented into anticoagulants, antiplatelets and thrombin inhibitors. Thrombin inhibitors are anticoagulants that inhibit the enzyme thrombin.
The global market for antithrombotic/anticoagulant drugs should reach $18.9 billion and $27.3 billion by 2016 and 2021, respectively, reflecting a five-year annual growth rate (CAGR) of 7.6%. The North American market is expected to grow from nearly $8 billion in 2016 to nearly $11 billion by 2021, demonstrating a five-year CAGR of 6.6%. In the Asia-Pacific region, the market should total $3.7 billion and about $6.3 billion by 2016 and 2021, respectively, on a five-year CAGR of 11.2%.
The growth of thrombin inhibitors is keying market expansion. Traditional anticoagulants and antiplatelets have witnessed a significant drop in market due to the decline in the development of new drugs, expiration of patents, availability of alternatives, such as thrombin inhibitors and low-priced generic drugs. Recent innovations and the emergence of novel thrombin inhibitors have led to the decline of traditional anticoagulants such as heparin and Vitamin K antagonists, as well. Low-molecular-weight heparins such as Lovenox, Fragmin, and warfarin have lost significant share the market.
The lack of new drug launches will slow the growth of the antiplatelet drug market, which should see declining prices as the market for novel thrombin inhibitors grows. This latter market, bolstered by Xarelto (rivaroxaban), Eliquis (apixaban), TNKase (tenecteplase) and Savaysa (edoxaban), should grow at the fastest CAGR (12.4%) among markets.
"The healthcare industry continues to advance its understanding of the molecular mechanisms of blood clotting, recombinant DNA technology, and antithrombotic proteins," says BCC Research analyst Anuj Pathak. "This has spurred development of novel anticoagulants that offer more specific activity on the coagulation cascade, predictable pharmacodynamics and pharmacokinetics, simpler dosing regimens and few or no laboratory monitoring requirements."
Antithrombotic/Anticoagulant Drugs: Techs and Global Markets (PHM119B) analyzes the market size of anticoagulants by revenue at manufacturers' sales levels, including low molecular weight heparins and oral anticoagulants, as well as breakdowns of antiplatelets and thrombin inhibitors. Global market drivers and trends, with data from 2015, estimates for 2016, and projections of CAGRs through 2021 also are provided.
Editors and reporters who wish to speak with the analyst should contact Steven Cumming at email@example.com.
Antithrombotic/Anticoagulant Drugs: Technologies and Global Markets( PHM119B )
Publish Date: Sep 2016